№ files_lp_4_process_3_115265
File format: docx
Character count: 3281
File size: 24 KB
This document lists various medications used for the prevention and treatment of migraines, including off-label drug uses and different pharmaceutical forms.
Year:
2023
Region / City:
Global
Topic:
Migraine Treatment and Prophylaxis
Document Type:
Pharmaceutical List
Author:
Not specified
Target Audience:
Healthcare professionals
Period of validity:
Ongoing
Approval Date:
Not specified
Date of modifications:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2019–2020
Region / country:
Australia
Subject:
Chronic migraine treatment and drug listing
Document type:
Public Summary Document (PSD)
Organization / authority:
Pharmaceutical Benefits Advisory Committee (PBAC), TGA
Drug:
Galcanezumab (Emgality)
Other drugs referenced:
Fremanezumab, Erenumab, Botox
Target population:
Adults with chronic migraine unresponsive to at least three prophylactic migraine medications
Administration form:
Injection 120 mg/1 mL pre-filled pen
Prescription restrictions:
Streamlined listing, treatment by neurologist required, specific clinical criteria for migraine frequency and prior treatment response
Consumer input:
Included 186 individuals, 2 health professionals, 1 organization
Cost analysis:
Cost-minimisation analysis (CMA) versus Botox
Risk sharing arrangement:
Included, with expenditure cap adjustments
Date:
[Date]
Patient:
[Patient’s First and Last Name]
Date of Birth:
[Patient’s Date of Birth]
Insurance Company:
[Insurance Company Name]
Subscriber ID #:
[Insurance Subscriber ID]
Subscriber Group #:
[Insurance Group ID]
Insurance Company Contact:
[Insurance Company Contact]
Insurance Company Address:
[Insurance Company Address]
Insurance Company City, State ZIP:
[Insurance Company City, State ZIP]
Medication:
VYEPTI® (eptinezumab-jjmr) [100 mg/300 mg]
Indication:
Preventive treatment of chronic/episodic migraine
ICD-10 Code:
[ICD-10 code]
Prior Treatments:
[List prior treatments with dates and reasons for discontinuation]
Dose Initiation:
[100 mg/300 mg]
Dose Escalation:
[If applicable, 300 mg]
Treatment Continuation:
[Current VYEPTI dose and response]
Physician:
[Physician’s Name]
Provider Identification Number:
[Provider Identification Number]
Practice Name:
[Name of Practice]
Practice Phone Number:
[Phone Number]
Enclosures:
Original Letter of Medical Necessity, patient clinical/diagnostic notes, relevant lab reports, published clinical references
Category:
Health Condition/ Disease
Subcategory:
Intervention
Last Updated:
2014-03-11
Keywords:
headache, migraine, attack, migrainous head pain, aura, neurological disorder, nervous system
Evidence:
B, C & D
Grade of Evidence:
B, C & D
Context:
A systematic review and critical analysis of dietary components that are self-reported as triggers for migraines, based on cross-sectional, case-control, experimental, and cohort studies.
Year:
2026
Patient Name:
[REDACTED]
Patient DOB:
[REDACTED]
Insurance Company:
[REDACTED]
Policy Number:
[REDACTED]
Group Number:
[REDACTED]
ICD10 Codes:
[REDACTED]
Test Name:
Hemiplegic Migraine Panel
CPT Codes:
81406x1, 81407x1, 81479x1
Laboratory:
GeneDx, Inc.
Laboratory Address:
207 Perry Parkway, Gaithersburg, MD 20877
Laboratory NPI:
1487632998
Laboratory TAXID:
205446298
Laboratory CLIA:
21D0969951
Ordering Provider:
[REDACTED]
Purpose:
Request for insurance coverage for medically necessary genetic testing
Clinical Indications:
Hemiplegic migraine with aura, family and personal medical history, uninformative prior genetic tests
Relevant Genes:
CACNA1A, SCN1A, ATP1A2, PRRT2
Clinical Features:
Aura, hemiplegic attacks, ataxia, intellectual disability, risk of seizures
Inheritance Pattern:
Autosomal dominant for familial hemiplegic migraine
Target Population:
Individuals with hemiplegic migraine symptoms and family history of similar disorders
References:
Albury et al. 2017; Huang et al. 2017; Pelzer et al. 2018; Jen JC 2001/2015; Noebels et al. 2012; Ebrahimi-Fakhari et al. 2015; Riant et al. 2010
Year:
2024
Location:
Tangent Theater, Trinity College Dublin, Ireland
Theme:
Clinical Neurology, Headache Disorders
Document type:
Conference Program
Organizing body:
Trinity College Dublin
Course director:
Dr Anhar Hassan
Speakers:
Prof Anhar Hassan, Ms Helen Cahill, Prof Miriam Galvin, Ms Naomi Thornton, Ms Sharon Moran, Dr Petya Mihaylova, Dr Siobhan Hutchinson, Ms Mary Pilladath, Dr Eddie O’Sullivan, Dr Nicholas Silver, Prof Brian McGuire
Target audience:
Healthcare professionals, neurologists, clinicians
Date:
February 2, 2024
Schedule:
09:00–16:30
Sessions:
Registration, Welcome, Keynote lectures, Panel discussions, Coffee breaks, Lunch, Closing remarks
Context:
Detailed agenda of a professional neurology conference including lectures, discussions, and practical sessions on migraine and other headache disorders
Year:
1997
Region / City:
United States
Topic:
Inpatient medication management
Document Type:
Manual
Organization / Institution:
Department of Veterans Affairs
Author:
Not specified
Target Audience:
Healthcare professionals in the Veterans Affairs system
Effective Period:
Ongoing updates
Approval Date:
December 1997
Revision Date:
August 2025
Year:
2005
Region / City:
United States
Topic:
Health Systems Design and Development
Document Type:
Release Notes
Organization / Institution:
Department of Veterans Affairs
Author:
Department of Veterans Affairs
Target Audience:
Health care professionals using CPRS
Period of Validity:
April 2006
Approval Date:
1/31/2005
Modification Date:
5/18/2005
Year:
2018
Region / City:
Rwanda
Theme:
Medication Management
Document Type:
Policy
Organization / Institution:
Ministry of Health, Rwanda
Author:
Chief Pharmacist
Target Audience:
Clinical Staff
Period of Validity:
Not specified
Approval Date:
August 2018
Revision Date:
July 2020
Purpose:
To ensure safe medication practices across clinical areas
Year:
2015
Region / City:
United Kingdom
Subject:
Medication management in care homes
Document Type:
Guidance / Good Practice Document
Organization:
Chiltern and Aylesbury Vale CCG
Authors:
Unoma Okoli, Seema Gadhia
Intended Audience:
Care home staff responsible for administering PRN medications
Approval Date:
21 May 2015
Review Date:
May 2018
References:
NICE SC1: 2014; CQC Pharmacy Tip: October 2008; British National Formulary April 2015; CCG Care Homes Guidance
Includes Appendices:
Yes (PRN template and example)
Year:
2010
Region / city:
Glendale, CO
Subject:
Pharmaceutical services, Bubble packaging
Document Type:
Sources Sought Notice
Agency:
Department of Veterans Affairs
Author:
Robert Woolfolk II
Target audience:
Service Disabled Veteran Owned Small Businesses, Veteran Owned Small Businesses, 8(a), HUBZone, and other Small Businesses
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Description:
The document outlines the market research announcement for a contractor to provide bubble packaging of medications for the Veterans Health Administration Salt Lake City Health Care System (VHASLCHCS).
Year:
2025
Region / city:
United States
Topic:
Healthcare, Medication Management, Software Upgrade
Document Type:
Release Notes
Organization / Institution:
Department of Veterans Affairs, Office of Information and Technology (OIT)
Author:
Department of Veterans Affairs
Target Audience:
Users and administrators of FDB Fwk Upgrade v4.5
Effective Period:
May 2025
Approval Date:
May 2025
Modification Date:
None listed
Note:
Year
Topic:
Health care, medication administration
Document type:
Agreement
Jurisdiction:
Commonwealth of Massachusetts
Regulatory reference:
105 CMR 430.160
Document type:
Acknowledgement form
Subject area:
Camp health services and medication administration
Role defined:
Health Care Consultant
Medical license types referenced:
Physician, Physician Assistant, Nurse Practitioner
Authorized activity:
Administration of prescription medications to campers
Conditions of administration:
Parental or guardian written permission required; medications delivered to and maintained by the camp
Oversight:
Professional oversight by the Health Care Consultant
Signatories:
Health Care Consultant
Applicable setting:
Camp
Source type:
Administrative compliance record
Year:
2007
Region / City:
United States
Topic:
Healthcare Software Updates
Document Type:
Release Notes
Organization / Institution:
Department of Veterans Affairs
Author:
VistA Health Systems Design & Development
Target Audience:
Healthcare professionals using VistA system
Effective Period:
2007
Approval Date:
03/29/2007
Modification Date:
October 2007
Year:
1997
Region / City:
United States
Subject:
Healthcare, Medication Management
Document Type:
User Manual
Organization:
Department of Veterans Affairs
Author:
Not specified
Target Audience:
Healthcare professionals in the Veterans Affairs system
Period of validity:
Not specified
Approval Date:
December 1997
Date of Changes:
May 2025
Revision History:
Yes
Context:
This document is a user manual detailing the management and updates of inpatient medication systems for healthcare professionals.
Note:
Date
December 30, 2025, at 02:
00 PM (Kabul, Afghanistan Time)
Year:
2021
Region / City:
Rockville, MD
Topic:
340B Drug Pricing Program
Document Type:
Guidance
Organization / Institution:
Health Resources and Services Administration (HRSA)
Author:
Apexus
Target Audience:
340B stakeholders, covered entities, health departments
Effective Period:
Ongoing
Approval Date:
2021
Date of Changes:
N/A
Year:
2019
Region / City:
Queensland
Topic:
Medications Management
Document Type:
Plan
Organization / Institution:
Department of Education
Author:
Not specified
Target Audience:
Staff members responsible for managing and administering medications in schools
Period of Validity:
5 years
Approval Date:
Not specified
Date of Last Review:
Not specified
Date of Changes:
Not specified
References:
Administration of medications in schools procedure, Queensland Health Departmental Standard
Description:
Plan for managing risks related to the purchase, possession, administration, and disposal of medications, including emergency medications in schools.
Year:
N/A
Region / City:
N/A
Topic:
Medication Authorization Process
Document Type:
Procedure
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Healthcare Providers
Period of Action:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Context:
Detailed guide on the prior authorization process for anti-obesity medications (AOMs), including steps for verification, documentation, and follow-up actions for insurance approval.